GlassScriptPhysician profile
Asma Khapra
NPI 1770702011
$49,013.30
in general payments reported to CMS, 2019-2025
42 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $316 · 2021: $1,116 · 2022: $5,606 · 2023: $8,201 · 2024: $7,119 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $14K · Food and Beverage: $6,551 · Travel and Lodging: $3,513 · Education: $81.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,433.86 |
| Consulting Fee | $13,656.25 |
| Food and Beverage | $6,550.74 |
| Travel and Lodging | $3,512.56 |
| Education | $81.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $28,761.44 | 2019-2025 | Tremfya, Stelara, Remicade |
| Ardelyx, INC. | $2,947.75 | 2023-2025 | Ibsrela |
| Janssen Global Services, LLC | $2,873.75 | 2023 | Stelara |
| Abbvie INC. | $2,391.49 | 2019-2025 | |
| Mahana Therapeutics, INC. | $2,376.03 | 2022 | |
| Genentech USA, INC. | $2,132.32 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,904.67 | 2021-2022 | |
| Celgene Corporation | $909.02 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $887.88 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $600.59 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.76 | 2019-2025 | Xifaxan |
| Qol Medical, LLC | $302.65 | 2019-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $275.20 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $238.21 | 2024-2025 | Sutab, Suflave |
| Genzyme Corporation | $199.86 | 2022-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $162.86 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $147.95 | 2020-2024 | Linzess |
| Gilead Sciences, INC. | $144.43 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $130.74 | 2024-2025 | Iqirvo, Bylvay |
| Celltrion USA INC. | $128.79 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Janssen Research & Development, LLC | $122.38 | 2024 | |
| Ferring Pharmaceuticals INC. | $116.60 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $108.08 | 2020-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $90.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $67.24 | 2024-2025 | Voquezna |
| Medtronic, INC. | $64.71 | 2024 | Interstim |
| Boston Scientific Corporation | $56.93 | 2021-2022 | |
| Echosens North America, INC. | $53.00 | 2024 | Fibroscan |
| Nestle Healthcare Nutrition INC. | $48.08 | 2023 | |
| Ucb, INC. | $38.81 | 2019 | |
| Daiichi Sankyo INC. | $37.83 | 2019-2022 | |
| Amgen INC. | $36.33 | 2021-2022 | |
| Digestive Care, INC. | $35.50 | 2025 | Pertzye |
| Aimmune Therapeutics, INC. | $34.16 | 2024 | |
| Pharmacosmos Therapeutics INC. | $34.14 | 2025 | Monoferric |
| Shionogi INC | $21.62 | 2019 | |
| Novo Nordisk INC | $18.82 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $18.68 | 2023 | Idacio |
| Organon LLC | $17.93 | 2025 | Hadlima, Renflexis |
| Albireo Pharma, INC. | $15.74 | 2022 | |
| Capsovision, INC. | $15.04 | 2024 | Capsocam Plus |
| Allergan, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Khapra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.